Vanguard Global Advisers
KLRS

Vanguard Global Advisers’s Kalaris Therapeutics KLRS Stock Holding History

Vanguard Global Advisers’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95K Hold
725
– – ﹤0.01% 3590
2026
Q1 		$4.18K Buy
+725
New +$6.43K ﹤0.01% 3574

Other funds holding KLRS

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Global Advisers's KLRS Position: Q2 2026 in Review

Vanguard Global Advisers held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 725 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

Vanguard Global Advisers first reported a position in KLRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.18K in Q1 2026. 52 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Vanguard Global Advisers held 725 shares of Kalaris Therapeutics worth $2.95K as of Q2 2026.
  • Vanguard Global Advisers left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3590 holding.
  • Vanguard Global Advisers first reported a position in Kalaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Kalaris Therapeutics position peaked at $4.18K in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.